Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate HELP Investigation Unit To Focus On Consumer Protection, Fraud

This article was originally published in The Gray Sheet

Executive Summary

The Senate Health, Education, Labor and Pensions Committee has formed a new investigations unit to "play an active role in consumer protection and to make sure that public money is spent well rather than wasted or squandered through fraud," committee Chairman Tom Harkin, D-Iowa, announced May 5

You may also be interested in...



Harkin At HELP's Helm: Industry Sees Senator's Prevention Focus As Positive

Incoming Senate HELP Committee Chairman Tom Harkin brings a longstanding interest in preventive medicine, a topic that has also been emphasized by the device industry as part of the ongoing health reform debate

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel